Trial Profile
Outcomes in chronic Kidney disease by purified Eicosapentaenoic acids for the prevention of HAZardous events: A Multicenter rAndomized control trial (OKEHAZAMA Trial)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2019
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms OKEHAZAMA Trial
- 10 Sep 2019 Planned number of patients changed from 200 to 300.
- 21 Mar 2014 New trial record